CJC-1295 + GHRP-2

This blend combines a longer‑acting GHRH analog with a fast‑acting ghrelin mimetic to create both sustained and acute components of GH release. CJC‑1295 is described as an engineered GHRH(1–29) analog that resists degradation and binds albumin, extending its functional half‑life; the protocol notes that a single dose can keep GH elevated for days and IGF‑1 elevated longer. GHRP‑2 is a synthetic ghrelin‑mimetic peptide that activates the GH secretagogue receptor (GHS‑R1a) and is associated with a rapid GH pulse that peaks within minutes. The combination is framed as synergistic because it stimulates GH secretion through two receptor pathways at once—sustained GHRH signaling plus a sharp secretagogue pulse—potentially yielding larger overall GH output than either alone. The protocol also calls out predictable ‘class’ effects: transient increases in appetite from ghrelin signaling, brief vasodilatory sensations (flushing/lightheadedness), and mild, short‑lived rises in ACTH/cortisol/prolactin that typically remain within physiologic ranges.